



(Please scan this QR code to view the Prospectus)



MODERN
Diagnostic & Research Centre

MODERN DIAGNOSTIC & RESEARCH CENTRE LIMITED

CIN: U85110DL2012PLC234368

Our Company was originally incorporated as "Modern Diagnostic & Research Centre Private Limited" as a private limited company, under the provisions of the Companies Act, 1956 vide Certificate of Incorporation dated April 16, 2012 issued by Registrar of Companies, Delhi having Corporate Identification Number U85110DL2012PTC234368. Subsequently, our Company was converted from a private limited company to public limited company pursuant to special resolution passed in the Extra-Ordinary General Meeting of the company held on November 16, 2024 and consequently the name of our Company was changed to "Modern Diagnostic & Research Centre Limited" pursuant to fresh certificate of incorporation dated December 18, 2024 issued to our Company by the Registrar of Companies, Central Processing Centre having Corporate Identification Number U85110DL2012PLC234368. For details of change in name and registered office of our Company, please refer to chapter titled "History and Corporate Matters" beginning on page no. 139 of the Prospectus.

Registered Office: Plot No H-64, 1st Floor BLK-H, Bai Nagar City landmark near Khetar Pal Hospital, Ramesh Nagar, West Delhi, New Delhi, Delhi-110015, India

Corporate Office: 363/4 Jawahar Nagar, New Railway Road, Gurugram, Sadar Bazar, Haryana-122001, India. **Website:** www.mdrindia.com; **E-Mail:** compliance@mdrindia.com; **Telephone No:** +91 9999474297

Company Secretary and Compliance Officer: Mrs. Priyanshu Yadav

PROMOTERS OF OUR COMPANY: MR. DEVENDRA SINGH YADAV, MRS. DEEPAI YADAV, MRS ASHA YADAV AND MR. JITENDRA SINGH

The Issue has been made in accordance with Chapter IX of the SEBI ICDR Regulations (IPO of Small and Medium Enterprises) and the equity shares are proposed to be listed on SME Platform of BSE Limited.

BASIS OF ALLOTMENT

INITIAL PUBLIC ISSUE OF 40,99,200 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF MODERN DIAGNOSTIC & RESEARCH CENTRE LIMITED ("MDRC" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ 90/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 80/- PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹ 3699.28 LAKHS ("THE ISSUE"), OF WHICH 2,06,400 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 90/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 80/- PER EQUITY SHARE AGGREGATING TO ₹ 185.76 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.e. NET ISSUE OF 38,92,800 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT A PRICE OF ₹ 90/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 80/- PER EQUITY SHARE AGGREGATING TO ₹ 3503.52 LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 27.15% AND 25.78%, RESPECTIVELY OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY. THE FACE VALUE OF THE EQUITY SHARES IS ₹ 10/- EACH.

ANCHOR INVESTOR ISSUE PRICE ₹ 90 PER EQUITY SHARE OF FACE VALUE OF ₹ 10 EACH
ISSUE PRICE: ₹ 90 PER EQUITY SHARE OF FACE VALUE ₹ 10 EACH.
THE ISSUE PRICE IS 9.00 TIMES OF THE FACE VALUE

RISKS TO INVESTORS:

- Any interruptions at our laboratories and diagnostic centres may affect our ability to process diagnostic tests, which in turn may adversely affect our business, results of operations and financial condition.
- Our business and prospects may be adversely affected if we are unable to maintain and grow our brand name and brand image.
- Majority of our operations are concentrated in state of Haryana and any adverse developments affecting Haryana could have an adverse effect on our business, results of operations and financial condition.
- We have certain outstanding litigation against us, an adverse outcome of which may adversely affect our business, reputation and results of operations.
- There may be significant dependence on key diagnostic equipment and core technology infrastructure, the failure of which could result in serious service disruptions.
- Our heavy reliance on pathology services as the primary revenue driver presents significant risks that could negatively impact our operations, financial performance, and long-term growth prospects.
- Failure to attract and retain skilled healthcare professionals and experienced technical staff may lead to compromised diagnostic service quality and negatively impact patient care delivery.
- We have experienced negative cash flows in the past. Any such negative cash flows in the future could affect our business, results of operations and prospects.
- We require certain approvals, licenses, registrations and permits to operate our business, and failure to obtain or renew them in a timely manner or maintain the statutory and regulatory permits and approvals required to operate our business may adversely affect our operations and financial conditions.
- Our Restated Financial Statements are prepared and signed by the Peer Review Auditor who is not Statutory Auditor of our Company as required under the provisions of ICDR.
- The Merchant Banker associated with the Issue has handled 69 public Issue out of which 2 Issue closed below Issue price on listing date below are the details:

Particulars	Numbers of Issues Handled	Issue closed below Issue price on listing date
Main Board	4	Nil
SME	65	2

12. Average cost of acquisition of Equity Shares held by the Promoters is mentioned below

Sr. No.	Name of Promoters	No. of Equity Shares held	Average Cost of Acquisition per equity share* (in ₹)
1.	Mr. Devendra Singh Yadav	92,40,000	0.90
2.	Mrs. Deepai Yadav	5,50,000	0.91
3.	Mrs. Asha Yadav	5,50,000	0.91
4.	Mr. Jitendra Singh	Nil	--

*The average cost of acquisition of Equity Shares by our Promoters has been calculated by taking into account the amount paid by them to acquire Shares and Shares allotted to them and as reduced by amount received on sell of shares i.e. net of sale consideration is divided by net quantity of shares acquired.

ANCHOR INVESTOR BIDDING DATE WAS: TUESDAY, DECEMBER 30, 2025 BID/ISSUE OPENED ON: WEDNESDAY, DECEMBER 31, 2025 BID/ISSUE CLOSED ON: FRIDAY, JANUARY 02, 2026

ISSUE PROGRAMME

This Issue was made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 229 of the SEBI ICDR Regulations and in compliance with Regulation 253 of the SEBI ICDR Regulations wherein not more than 50.00% of the Net Issue was made available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") (the "QIB Portion"), provided that our Company in consultation with the BRML allocated up to 60.00% of the QIB Portion to Anchor Investors on a discretionary basis ("Anchor Investor Portion"). Out of which 33.33% of the Anchor Investor Portion shall be reserved for domestic Mutual Funds and 6.67% for life insurance companies and pension funds, subject to valid Bids being received from the domestic Mutual Funds at or above the Anchor Investor Allocation Price in accordance with the SEBI ICDR Regulations. Further, 5.00% of the Net QIB Portion was made available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion was made available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15.00% of the Net Issue was made available for allocation on a proportionate basis to Non-Institutional Investors and not less than 35.00% of the Net Issue was made available for allocation to Individual Investors in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Issue Price. All Potential Bidders, other than Anchor Investors, were required to participate in the Issue by mandatorily utilising the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amounts were blocked by the Self Certified Syndicate Banks ("SCSBs") or under the UPI Mechanism, to the extent of respective Bid Amounts. Anchor Investors were not permitted to participate in the Issue through the ASBA process. For details, please refer to the chapter titled "Issue Procedure" on page 222 of the Prospectus.

The bidding for Anchor Investors was opened and closed on Tuesday, December 30, 2025. The company received 09 Anchor Investors application for 20,32,000 Equity Shares. The Anchor Investor Allocation Price was finalized at ₹ 90 per Equity Share. A total of 11,61,600 Equity Shares were allotted under the Anchor Investor portion aggregating to ₹ 10,45,44,000.

The issue (excluding Anchor Investor Portion) received 1,90,634 applications for 1,03,44,44,800 Equity Shares (before rejections and after removing Multiple/Duplicate bids, and Bid not Banked) resulting in 352.14 times subscription (including reserved portion of market maker). The Details of the total Applications received in the Issue from various categories are as under

Detail of the Before rejection Applications Received:

Sr. No.	Category	No of Application	No of Shares	Reserved	No of Times Subscription	Amount
1	Qualified Institutional Buyers (Excluding Anchor Portion)	90	15,12,32,000	7,82,400	193.29	13,61,08,80,000
2	Non-Institutional Investors (More than 300,000/- to 1,000,000/-)	15,023	7,54,35,200	1,92,000	392.89	6,76,88,94,400.00
3	Non-Institutional Investors (More than 1,000,000/-)	28,948	33,82,20,800	3,93,600	859.30	30,43,96,96,000.00
4	Individual Investors*	1,46,672	46,93,50,400	13,63,200	344.30	42,23,54,36,800.00
5	Market Maker	01	2,06,400	2,06,400	1.00	1,85,76,000
	Total	1,90,634	1,03,44,44,800	29,37,600	352.14	93,09,34,83,200.00

*Individual Investors means Individual Investors who applied for minimum application size for two lots.

Final Demand

A summary of the final demand as per BSE as on the Bid/Issue Closing Date at different Bid Prices is as under:

Sr No	Rate	Shares	% To Total	Cumulative Total	Cumulative % To Total
1	85	20,14,400	0.18	20,14,400	0.18
2	86	2,62,400	0.02	22,76,800	0.20
3	87	2,60,800	0.02	25,37,600	0.22
4	88	5,93,600	0.05	31,31,200	0.28
5	89	6,84,800	0.06	38,16,000	0.34
6	90	1,12,40,33,600	99.96	1,12,78,49,600	100.00
	TOTAL	1,12,78,49,600	100.00		

1) Allocation to Individual Investors (After Rejections): The Basis of Allotment to the Individual Investors, who have bid at cut-off Price or at or above the Issue Price of ₹ 90 per equity shares, was finalized in consultation with BSE. The category was subscribed by 337.84 times i.e. for 46,05,40,800 Equity Shares. Total number of shares allotted in this category is 13,63,200 Equity Shares to 426 successful applicants. The category wise details of the Basis of Allotment as under:

Sr No	Category	No. Of Applications Received	% Of Total	Total No. of Equity Shares Applied	% To Total	No. Of Equity Shares Allotted Per Bidder	Ratio	Total No. Of Equity Shares Allotted
1	3200	1,43,919	100.00	46,05,40,800	100.00	3200	5.1689	13,63,200
	Total	1,43,919	100.00	46,05,40,800	100.00			13,63,200

2) Allocation to Non-Institutional Investors (More than 300,000/- to 1,000,000/-) (After Rejections): The Basis of Allotment to Other than Individual Investors (More than 300,000/- to 1,000,000/-), who have bid at Issue Price of ₹ 90/- per equity shares or above, was finalized in consultation with BSE. The category was subscribed by 388.05 times i.e. for 7,45,05,600 Equity Shares. The total number of shares allotted in this category is 1,92,000 Equity Shares to 40 successful applicants. The category wise details of the Basis of Allotment are as under:

Sr No	Category	No. Of Applications Received	% Of Total	Total No. of Equity Shares Applied	% To Total	No. Of Equity Shares Allotted Per Bidder	Ratio	Total No. Of Equity Shares Allotted
1	4,800	13,730	92.53	6,59,04,000	88.46	4,800	37.13730	1,77,600
2	6,400	544	3.67	34,81,600	4.67	4,800	1.544	4,800
3	8,000	184	1.24	14,72,000	1.98	4,800	1.184	4,800
4	9,600	380	2.56	36,48,000	4.90	4,800	1.380	4,800
	TOTAL	14,838	100.00	7,45,05,600	100.00			1,92,000

3) Allocation to Non-Institutional Investors (More than 1,000,000/-) (After Rejections): The Basis of Allotment to Other than Individual Investors (More than 1,000,000/-), who have bid at Issue Price of ₹ 90/- per equity shares or above, was finalized in consultation with BSE. The category was subscribed by 655.99 times i.e. for 33,69,18,400 Equity Shares. The total number of shares allotted in this category is 3,93,600 Equity Shares to 82 successful applicants. The category wise details of the Basis of Allotment are as under:

Sr No	Category	No. Of Applications Received	% Of Total	Total No. of Equity Shares Applied	% To Total	No. Of Equity Shares Allotted Per Bidder	Ratio	Total No. Of Equity Shares Allotted
1	11,200	26,893	93.59	30,12,01,600	89.4	4,800	77.26893	3,69,600
2	12,800	919	3.20	1,17,63,200	3.49	4,800	3.919	14,400
3	14,400	273	0.95	39,31,200	1.17	4,800	1.273	4,800
4	16,000	190	0.66	30,40,000	0.9	4,800	1.190	4,800
5	17,600	44	0.15	7,74,400	0.23	4,800	0.44	0
6	19,200	34	0.12	6,52,800	0.19	4,800	0.34	0
7	20,800	26	0.09	5,40,800	0.16	4,800	0.26	0
8	22,400	88	0.31	19,71,200	0.59	4,800	0.88	0
9	24,000	32	0.11	7,88,000	0.23	4,800	0.32	0
10	25,600	14	0.05	3,58,400	0.11	4,800	0.14	0
11	27,200	9	0.03	2,44,800	0.07	4,800	0.09	0
12	28,800	9	0.03	2,59,200	0.08	4,800	0.09	0
13	30,400	9	0.03	2,73,600	0.08	4,800	0.09	0
14	32,000	40	0.14	12,80,000	0.38	4,800	0.40	0
15	33,600	24	0.08	8,06,400	0.24	4,800	0.24	0
16	35,200	11	0.04	3,87,200	0.11	4,800	0.11	0
17	36,800	12	0.04	4,41,600	0.13	4,800	0.12	0
18	38,400	3	0.01	1,15,200	0.03	4,800	0.03	0
19	40,000	9	0.03	3,60,000	0.11	4,800	0.09	0
20	41,600	4	0.01	1,66,400	0.05	4,800	0.04	0
21	43,200	3	0.01	1,29,600	0.04	4,800	0.03	0
22	44,800	6	0.02	2,68,800	0.08	4,800	0.06	0
23	46,400	3	0.01	1,39,200	0.04	4,800	0.03	0
24	48,000	17	0.06	8,16,000	0.24	4,800	0.17	0
25	49,600	1	0.00	49,600	0.01	4,800	0.01	0
26	51,200	9	0.03	4,60,800	0.14	4,800	0.09	0
27	52,800	3	0.01	1,58,400	0.05	4,800	0.03	0
28	54,400	3	0.01	1,63,200	0.05	4,800	0.03	0
29	56,000	12	0.04	6,72,000	0.2	4,800	0.12	0
30	57,600	3	0.01	1,72,800	0.05	4,800	0.03	0
31	60,800	2	0.01	1,21,600	0.04	4,800	0.02	0
32	64,000	2	0.01	1,28,000	0.04	4,800	0.02	0
33	65,600	1	0.00	65,600	0.02	4,800	0.01	0
34	67,200	1	0.00	67,200	0.02	4,800	0.01	0
35	72,000	1	0.00	72,000	0.02	4,800	0.01	0
36	75,200	2	0.01	1,50,400	0.04	4,800	0.02	0
37	78,400	1	0.00	78,400	0.02	4,800	0.01	0
38	80,000	3	0.01	2,40,000	0.07	4,800	0.03	0
39	89,600	1	0.00	89,600	0.03	4,800	0.01	0
40	96,000	3	0.01	2,88,000	0.09	4,800	0.03	0
41	1,05,600	1	0.00	1,05,600	0.03	4,800	0.01	0

Continued From Previous Page...

Sr No	Category	No. Of Applications Received	% Of Total	Total No. of Equity Shares Applied	% To Total	No. Of Equity Shares Allotted Per Bidder	Ratio	Total No. Of Equity Shares Allotted
42	1,08,800	1	0.00	1,08,800	0.03	4,800	0:01	0
43	1,12,000	2	0.01	2,24,000	0.07	4,800	0:02	0
44	1,28,000	1	0.00	1,28,000	0.04	4,800	0:01	0
45	1,32,800	1	0.00	1,32,800	0.04	4,800	0:01	0
46	1,39,200	2	0.01	2,78,400	0.08	4,800	0:02	0
47	1,45,600	1	0.00	1,45,600	0.04	4,800	0:01	0
48	1,53,600	1	0.00	1,53,600	0.05	4,800	0:01	0
49	1,60,000	1	0.00	1,60,000	0.05	4,800	0:01	0
50	2,16,000	1	0.00	2,16,000	0.06	4,800	0:01	0
51	2,68,800	1	0.00	2,68,800	0.08	4,800	0:01	0
52	2,83,200	1	0.00	2,83,200	0.08	4,800	0:01	0
53	2,92,800	1	0.00	2,92,800	0.09	4,800	0:01	0
54	7,53,600	1	0.00	7,53,600	0.22	4,800	0:01	0
TOTAL		28736	100	33,69,18,400	100.00			393600

4) Allocation to QIBs excluding Anchor Investors (After Rejections): The Basis of Allotment to QIBs, who have bid at Issue Price of ₹ 90 per Equity Shares or above, was finalized in consultation with BSE. The category was subscribed by 193.29 times i.e. for 15,12,32,000 Equity shares. The total number of shares allotted in this category is 7,82,400 Equity Shares to 80 successful applicants. The category wise details of the Basis of Allotment are as under:

Category	FIS/Banks	MFS	IC'S	NBFC'S	AIF	FPFI	VCs	Total
Allotment	-	-	8,000	1,39,200	4,67,200	1,61,600	6,400	7,82,400

5) Allocation to Anchor Investors (After Rejections): The Company in consultation with the BRLM has allotted 11,61,600 Equity Shares to 09 Anchor Investors at Anchor Investor Issue Price of ₹ 90 per Equity Shares in accordance with the SEBI ICDR Regulations. The category wise details of the Basis of Allotment are as under:

Category	FIS/Banks	MFS	IC'S	NBFC'S	AIF	FPFI	Others	Total
Anchor	-	-	-	1,13,600	10,48,000	-	-	11,61,600

6) Allocation to Market Maker (After Rejections): The Basis of Allotment to Market Maker who have bid at Issue Price of ₹ 90 per Equity Shares or above, was finalized in consultation with BSE. The category was subscribed by 1.00 times i.e. for 2,06,400 Equity shares. The total number of shares allotted in this category is 2,06,400 Equity Shares. The category wise details of the Basis of Allotment are as under:

No. of Shares Applied for (Category wise)	No. of applications received	% of Total	Total No. of Equity Shares applied in this Category	% of Total	No. of Equity Shares allocated/ allotted per Applicant	Ratio	Total Number of shares allotted	Surplus/ Deficit
2,06,400	1	100	2,06,400	100	2,06,400	1:1	2,06,400	-
TOTAL	1	100	2,07,000	100	2,07,000		2,06,400	-

The Board of Directors of the Company on January 05, 2026, has taken on record the Basis of Allotment of Equity Shares as approved by BSE Limited and has allotted the Equity Shares to various successful bidders. The Allotment Advices-cum-Intimations and/or notices have been forwarded to the email ids and/or address of the Applicants as registered with the depositories/as filled in the application form. Further, the instructions to Self-Certified Syndicate Banks for unblocking the funds & transfer to Public Issue Account have been issued on or before January 06, 2026 and payment to non-syndicate brokers has been issued on or before January 06, 2026. In case the same is not received within two working days, investors may contact at the address given below. The equity shares allotted to the successful allottees have been uploaded on or before January 06, 2026 for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company will file the Listing application with BSE Limited on or before January 06, 2026. The trading will commence on January 07, 2026.

INVESTORS, PLEASE NOTE

The details of the allotment made would also be hosted on the website of the Registrar to the issue, **MUG Intime India Private Limited (Formerly Link Intime India Private Limited)** at www.in.mgms.mug.com. All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the First/ Sole applicants, serial number of the Bid cum Application Form, number of shares applied for and Bank Branch where the application had been lodged and payment details at the address of the Registrar given below:

MUG Intime India Private Limited
(Formerly Link Intime India Private Limited)

SEBI Registration Number: INR000004058

Address: C 101, 247 Park, Lal Bahadur Shastri Marg, Vikhroli (West), Mumbai 400 083, India

Tel. No.: +91-22-4918 6000/ +91 8108114949

Email Id: modern@diagnostic.smeipo@n.mgms.mug.com

Investors Grievance Id: modern@diagnostic.smeipo@n.mgms.mug.com

Website: www.in.mgms.mug.com

Contact Person: Shantl GopalKishnan

CIN: U67190MH1999PTC118368

On behalf of Board of Directors
For, Modern Diagnostic & Research Centre Limited
Sd/-
Mr. Devendra Singh Yadav
Managing Director

Place: Delhi

Date: January 06, 2026

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF MODERN DIAGNOSTIC & RESEARCH CENTRE LIMITED.

Modern Diagnostic & Research Centre Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public issue of its Equity Shares and has filed the RHP with the Registrar of Companies, Delhi on December 23, 2025 and transferred with SEBI and the Stock Exchanges. The RHP is available on the websites of SEBI at www.sebi.gov.in, website of the Company at www.mdc.india.com, the website of the BRLM to the issue at www.bseindia.com, the website of BSE SME i.e. www.bseindia.com, respectively. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the RHP including the section titled "Risk Factors" beginning on page 23 of the Prospectus.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. state securities laws. The Equity Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the Securities Act and the applicable laws of each jurisdiction where such offers and sales are made. There will be no public offering in the United States.